Magnetic resonance biomarker assessment software (MR-BIAS): an automated open-source tool for the ISMRM/NIST system...

Objective.To provide an open-source software for repeatable and efficient quantification ofT₁andT₂relaxation times with the ISMRM/NIST system phantom. Quantitative magnetic resonance imaging (qMRI) biomarkers have the potential to improve disease detection, staging and monitoring of treatment response. Reference objects, such as the system phantom, play a major role in translating qMRI methods into the clinic. The currently available open-source software for ISMRM/NIST system phantom analysis, Phantom Viewer (PV), includes manual steps that are subject to variability.Approach.We developed the Magnetic Resonance BIomarker Assessment Software (MR-BIAS) to automatically extract system phantom relaxation times. The inter-observer variability (IOV) and time efficiency of MR-BIAS and PV was observed in six volunteers analysing three phantom datasets. The IOV was measured with the coefficient of variation (CV) of percent bias (%bias) inT₁andT₂with respect to NMR reference values. The accuracy of MR-BIAS was compared to a custom script from a published study of twelve phantom datasets. This included comparison of overall bias and %bias for variable inversion recovery (T₁^VIR), variable flip angle (T₁^VFA) and multiple spin-echo (T₂^MSE) relaxation models.Main results.MR-BIAS had a lower mean CV withT₁^VIR(0.03%) andT₂^MSE(0.05%) in comparison to PV withT₁^VIR(1.28%) andT₂^MSE(4.55%). The mean analysis duration was 9.7 times faster for MR-BIAS (0.8 min) than PV (7.6 min). There was no statistically significant difference in the overall bias, or the %bias for the majority of ROIs, as calculated by MR-BIAS or the custom script for all models.Significance.MR-BIAS has demonstrated repeatable and efficient analysis of the ISMRM/NIST system phantom, with comparable accuracy to previous studies. The software is freely available to the MRI community, providing a framework to automate required analysis tasks, with the flexibility to explore open questions and accelerate biomarker research.